Strides Pharma Q1 FY27: Revenue up 13%, PAT +56.7%

Key takeaway from the quarter

Strides Pharma Science Limited reported a higher top line in Q1 FY27, even as it flagged geopolitical disruptions during the period. Consolidated revenue from operations rose 13.0% year-on-year to ₹12,654.07 million. EBITDA increased 5.4% YoY to ₹2,298 million, pointing to continued operating momentum. The company also reported a 14.0% growth in gross margins. Reported net profit after tax (PAT) jumped 56.7% YoY to ₹1,654.93 million, supported by an exceptional gain linked to Pivot Path stake dilution. Operational PAT was reported at ₹1,231 million, with operational EPS at ₹13.4.

Financial performance snapshot

For the quarter ended June 30, 2026 (Q1 FY27), Strides posted total income of ₹12,702.97 million, up from ₹11,283.19 million a year earlier. Revenue from operations increased from ₹11,197.36 million in the corresponding quarter to ₹12,654.07 million. The rise in earnings was sharper than the rise in operating profit due to non-recurring income recorded during the quarter. The company disclosed an exceptional gain of ₹742.07 million from the Pivot Path stake dilution, which contributed to the reported PAT. Excluding the non-recurring item, the company said operational profitability remained robust.

Profitability: EBITDA rise despite disruptions

EBITDA for Q1 FY27 grew 5.4% YoY to ₹2,298 million. The company also reported a 14.0% growth in gross margins, despite geopolitical disruptions. The mix of stable US revenues and higher contribution from other markets was part of the quarter’s narrative, as disclosed in the segment commentary. Strides’ operational profitability indicators were presented separately from the reported PAT, highlighting the impact of exceptional items. Operational PAT was reported at ₹1,231 million during the quarter. Operational EPS stood at ₹13.4.

Segment performance: US stable, Ex-US drives growth

In the US market, Strides reported revenue of ₹6,282 million in Q1 FY27, described as steady. The company indicated that new product approvals are expected in H2 FY27. Outside the US, performance was stronger, with Ex-US revenues rising 17% YoY to ₹5,875 million. This Ex-US growth was cited as a key driver behind the consolidated revenue expansion. The combined segment numbers align with the overall consolidated revenue from operations of ₹12,654.07 million.

Exceptional gain lifts reported net profit

Strides’ reported net profit after tax for Q1 FY27 was ₹1,654.93 million, up from ₹1,055.93 million in the same period last year. The quarter included an exceptional gain of ₹742.07 million from the Pivot Path stake dilution. The company’s reported net profit in crore terms was also cited as ₹165.49 crore for Q1 FY27. The distinction between reported profit and operational performance is relevant for investors tracking recurring profitability. The company separately disclosed operational PAT of ₹1,231 million.

Important numbers table

Geography and business mix table

Dividend record date and investor call

The company scheduled an earnings conference call on July 31, 2026 at 5:00 PM IST to discuss its unaudited financial results for the quarter ended June 30, 2026. Strides also fixed Friday, July 31, 2026 as the record date to determine shareholder eligibility for a final dividend of ₹5 per equity share. The dividend represents 50% of the face value of ₹10 per share for the financial year ended March 31, 2026. Such dates are typically used to finalise the list of shareholders entitled to receive the dividend.

Stock market context and identifiers

The results were disclosed to the exchange, with the source cited as BSE. Strides Pharma Science is classified under Sector: Healthcare and Industry: Pharmaceuticals and Drugs. The BSE scrip code referenced in the details is 532531. Investors often track reported numbers such as consolidated revenue, EBITDA, and PAT alongside one-off items to understand the quarter’s underlying performance.

Why the Q1 FY27 result matters

The quarter shows that Strides delivered double-digit revenue growth while maintaining EBITDA growth, even with disruptions referenced in the update. The reported PAT increase is notable, but it is also tied to the exceptional gain from Pivot Path stake dilution. Operational disclosures such as operational PAT of ₹1,231 million and operational EPS of ₹13.4 provide additional context on recurring profitability. The steady US revenue number and the 17% YoY growth in Ex-US markets underline where the incremental growth came from during the quarter. The company’s mention of expected new product approvals in H2 FY27 adds a near-term operational milestone for investors to track.

Conclusion

Strides Pharma’s Q1 FY27 update showed revenue from operations rising 13% YoY to ₹12,654.07 million, EBITDA increasing to ₹2,298 million, and reported PAT climbing to ₹1,654.93 million, aided by an exceptional gain. The company will discuss the quarter on its July 31, 2026 earnings call, while the same date serves as the record date for a final dividend of ₹5 per share.